Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome

@inproceedings{Yuan2017SmallmoleculeFD,
  title={Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome},
  author={Xuan Yuan and Eleni Gavriilaki and Jane A. Thanassi and Guangwei Yang and Andrea C. Baines and Steven D. Podos and Yongqing Huang and Mingjun Huang and Robert A Brodsky},
  booktitle={Haematologica},
  year={2017}
}
Paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome are diseases of excess activation of the alternative pathway of complement that are treated with eculizumab, a humanized monoclonal antibody against the terminal complement component C5. Eculizumab must be administered intravenously, and moreover some patients with paroxysmal nocturnal hemoglobinuria on eculizumab have symptomatic extravascular hemolysis, indicating an unmet need for additional therapeutic approaches. We… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 7 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 44 references

A phase ia doseescalation study of the antifactor D monoclonal antibody fragment FCFD 4514 S in patients with geographic atrophy

  • DV Do, DJ Pieramici, M vanLookerenCampagne
  • Retina
  • 2014

Similar Papers

Loading similar papers…